

Massimo Levrero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4778796/publications.pdf>

Version: 2024-02-01

47
papers

7,387
citations

136950

32
h-index

243625

44
g-index

48
all docs

48
docs citations

48
times ranked

7164
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. <i>Journal of Clinical Virology</i> , 2022, 150-151, 105150.	3.1	14
2	Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus. <i>Hepatology</i> , 2021, 73, 861-864.	7.3	26
3	Downregulation of miR-326 and its host gene <i>ARRESTIN1</i> induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542.	4.6	8
4	External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study. <i>Transplant International</i> , 2021, 34, 535-545.	1.6	2
5	Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 1715.	2.4	12
6	The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond. <i>Cancers</i> , 2021, 13, 3115.	3.7	6
7	Structural Variations of Vaginal and Endometrial Microbiota: Hints on Female Infertility. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 350.	3.9	67
8	A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro. <i>Viruses</i> , 2020, 12, 251.	3.3	8
9	Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication. <i>Nature Communications</i> , 2020, 11, 419.	12.8	19
10	Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. <i>Gut</i> , 2020, 69, 2016-2024.	12.1	92
11	Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells. <i>Journal of Visualized Experiments</i> , 2019, . .	0.3	3
12	Non-invasive biomarkers for chronic hepatitis B virus infection management. <i>Antiviral Research</i> , 2019, 169, 104553.	4.1	38
13	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	3.7	341
14	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342
15	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, 615-625.	3.7	204
16	Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. <i>Viruses</i> , 2018, 10, 591.	3.3	30
17	Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. <i>Current Opinion in Virology</i> , 2018, 30, 80-89.	5.4	44
18	Genome-wide identification of direct HBx genomic targets. <i>BMC Genomics</i> , 2017, 18, 184.	2.8	52

#	ARTICLE	IF	CITATIONS
19	PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. <i>Hepatology</i> , 2017, 66, 398-415.	7.3	101
20	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	30.7	251
21	Directly acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C. <i>Liver International</i> , 2017, 37, 1122-1127.	3.9	60
22	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 897-909.	3.7	125
23	Challenges to a Cure for HBV Infection. <i>Seminars in Liver Disease</i> , 2017, 37, 231-242.	3.6	31
24	Mechanisms of HBV-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, S84-S101.	3.7	664
25	HBV cure: why, how, when?. <i>Current Opinion in Virology</i> , 2016, 18, 135-143.	5.4	50
26	Aiming for cure in HBV and HDV infection. <i>Journal of Hepatology</i> , 2016, 65, 835-848.	3.7	66
27	Current treatments for chronic hepatitis B virus infections. <i>Current Opinion in Virology</i> , 2016, 18, 109-116.	5.4	70
28	Ribavirin restores IFN α responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. <i>Gut</i> , 2016, 65, 672-682.	12.1	16
29	IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. <i>PLoS ONE</i> , 2015, 10, e0142599.	2.5	66
30	Towards an HBV cure: state-of-the-art and unresolved questions – report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	12.1	234
31	p53 and p73 in cancer, an unresolved ‘family’ puzzle of complexity, redundancy and hierarchy. <i>FEBS Letters</i> , 2014, 588, 2590-2599.	2.8	39
32	HCV core-mediated activation of latent TGF- β 2 via thrombospondin drives the crosstalk between hepatocytes and stromal environment. <i>Journal of Hepatology</i> , 2013, 59, 1160-1168.	3.7	53
33	Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. <i>Seminars in Liver Disease</i> , 2013, 33, 147-156.	3.6	96
34	IFN α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. <i>Journal of Clinical Investigation</i> , 2012, 122, 529-537.	8.2	492
35	Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. <i>Journal of Hepatology</i> , 2011, 55, 996-1003.	3.7	361
36	Control of hepatitis B virus replication by innate response of HepaRG cells. <i>Hepatology</i> , 2010, 51, 63-72.	7.3	124

#	ARTICLE	IF	CITATIONS
37	Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19975-19979.	7.1	403
38	Control of cccDNA function in hepatitis B virus infection. Journal of Hepatology, 2009, 51, 581-592.	3.7	476
39	Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Myeloma Cells Sensitive and Resistant to Bortezomib.. Blood, 2009, 114, 1837-1837.	1.4	0
40	Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model.. Blood, 2008, 112, 1712-1712.	1.4	0
41	Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones. Gastroenterology, 2006, 130, 823-837.	1.3	401
42	Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.. Blood, 2005, 106, 613-613.	1.4	0
43	Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nature Cell Biology, 2003, 5, 552-558.	10.3	249
44	The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature, 1999, 399, 806-809.	27.8	863
45	Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. Hepatology, 1999, 30, 510-516.	7.3	40
46	Binding of CDK9 to TRAF2. Journal of Cellular Biochemistry, 1998, 71, 467-478.	2.6	34
47	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. , 0, .		2